Drugs / iNeo-Vac-T01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07504523 | Nov 2023 → Dec 2027 expected | colorectal cancer | Ying Yuan, MD | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iNeo-Vac-T01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07504523 ↗ |
| Action | Deplete | “These specific T cells recognize and kill tumor cells expressing the corresponding neoantigens” NCT07504523 ↗ |
| Modality | Cell therapy | “personalized T-cell therapy based on tumor neoantigens” NCT07504523 ↗ |